Public Release: 

Laser-controlled molecular switch turns blood clotting on, off on command

Selective release of DNA from gold nanorods switches blood clotting on and off

PLOS

IMAGE?

IMAGE: DNA-controlled nanoparticles work as a two-way switch for blood clotting. view more

Credit: Helena de Puig

Researchers have designed tiny, light-controlled gold particles that can release DNA controls to switch blood clotting off and on. The results are reported July 24 in the open access journal PLOS ONE by Kimberly Hamad-Schifferli and colleagues from the Massachusetts Institute of Technology.

The two-way switch for blood clotting relies on the ability of two gold nanoparticles to selectively release different DNA molecules from their surface under different wavelengths of laser excitation. When stimulated by one wavelength, one nanorod releases a piece of DNA that binds the blood protein thrombin and blocks clot formation. When the complementary DNA piece is released from the other nanorod, it acts as an antidote and releases thrombin, restoring clotting activity.

Natural blood clotting is precisely synchronized to occur at the right time and place. Wound healing, surgery and other conditions require manipulation of this process, typically through the use of anticoagulants like heparin or warfarin. However, these drugs are inherently one-sided as they can only block clotting, and reversing their effects depends on removing them from the bloodstream. The methods described in this research open up new possibilities for more precise, selective control of the blood clotting process during therapy.

###

Citation: de Puig H, Cifuentes Rius A, Flemister D, Baxamusa SH, Hamad-Schifferli K (2013) Selective Light-Triggered Release of DNA from Gold Nanorods Switches Blood Clotting On and Off. PLOS ONE 8(7): e68511. doi:10.1371/journal.pone.0068511

Financial Disclosure: This work was funded by the National Science Foundation grant# DMR #0906838. http://www.nsf.gov/. HdP was supported by a fellowship from La Caixa Foundation (Spain). http://obrasocial.lacaixa.es/laCaixaFoundation/home_en.html. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interest Statement: The authors have declared that no competing interests exist.

PLEASE LINK TO THE SCIENTIFIC ARTICLE IN ONLINE VERSIONS OF YOUR REPORT (URL goes live after the embargo ends): http://dx.plos.org/10.1371/journal.pone.0068511

Disclaimer: This press release refers to upcoming articles in PLOS ONE. The releases have been provided by the article authors and/or journal staff. Any opinions expressed in these are the personal views of the contributors, and do not necessarily represent the views or policies of PLOS. PLOS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.

About PLOS ONE: PLOS ONE is the first journal of primary research from all areas of science to employ a combination of peer review and post-publication rating and commenting, to maximize the impact of every report it publishes. PLOS ONE is published by the Public Library of Science (PLOS), the open-access publisher whose goal is to make the world's scientific and medical literature a public resource.

All works published in PLOS ONE are Open Access. Everything is immediately available--to read, download, redistribute, include in databases and otherwise use--without cost to anyone, anywhere, subject only to the condition that the original authors and source are properly attributed. For more information about PLOS ONE relevant to journalists, bloggers and press officers, including details of our press release process and our embargo policy, see the everyONE blog at http://everyone.plos.org/media.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.